Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study
Authors:
- Tony M KeavenyTKTony M Keaveny
- Annette L AdamsAAAnnette L Adams
- Eric S OrwollEOEric S Orwoll
- Sundeep KhoslaSKSundeep Khosla
- Ethel S SirisESEthel S Siris
- Michael R McClungMMMichael R McClung
- Mary L BouxseinMBMary L Bouxsein
- Shireen FatemiSFShireen Fatemi
- David C LeeDLDavid C Lee
- David L KopperdahlDKDavid L Kopperdahl
Open Access
- 11 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (10) , 1424-1433
Abstract
Randomized trials have not been performed, and may never be, to determine if osteoporosis treatment prevents hip fracture in men. Addressing that evidence gap, we analyzed data from an observational study of new hip fractures in a large integrated healthcare system to compare the reduction in hip fractures associated with standard-of-care osteoporosis treatment in men versus women. Sampling from 271,389 patients aged ≥ 65 who had a hip-containing CT scan during care between 2005 and 2018, we selected all who subsequently had a first hip fracture (cases) after the CT scan (start of observation) and a sex-matched equal number of randomly selected patients. From those, we analyzed all who tested positive for osteoporosis (DXA-equivalent hip BMD T-score ≤ −2.5, measured from the CT scan using VirtuOst). We defined “treated” as at least six months of any osteoporosis medication by prescription fill data during follow-up; “not-treated” was no prescription fill. Sex-specific odds ratios of hip fracture for treated vs not-treated patients were calculated by logistic regression; adjustments included age, BMD T-score, BMD-treatment interaction, BMD, race/ethnicity, and seven baseline clinical risk factors. At two-year follow-up, 33.9% of the women (750/2,211 patients) and 24.0% of the men (175/728 patients) were treated primarily with alendronate; 51.3% and 66.3%, respectively, were not-treated; and 721 and 269, respectively, had a first hip fracture since the CT scan. Odds ratio of hip fracture for treated vs not-treated was 0.26 (95% confidence interval: 0.21–0.33) for women and 0.21 (0.13–0.34) for men; the ratio of these odds ratios (men:women) was 0.81 (0.47–1.37), indicating no significant sex effect. Various sensitivity and stratified analyses confirmed these trends, including results at five-year follow-up. Given these results and considering the relevant literature, we conclude that osteoporosis treatment prevents hip fracture similarly in both sexes.Keywords
Funding Information
- National Institutes of Health (R01 AR074958)
This publication has 33 references indexed in Scilit:
- Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosisOsteoporosis International, 2020
- Screening for Osteoporosis to Prevent FracturesJAMA, 2018
- Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS)Journal of Bone and Mineral Research, 2018
- Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures—A Post Hoc Analysis of the SCOOP StudyJournal of Bone and Mineral Research, 2018
- Assessment of incident spine and hip fractures in women and men using finite element analysis of CT scansJournal of Bone and Mineral Research, 2013
- Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAXJournal of Bone and Mineral Research, 2012
- Fracture prevention in Kaiser Permanente Southern CaliforniaOsteoporosis International, 2011
- Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled studyJournal of Bone and Mineral Research, 2010
- Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 2000
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998